


About Albemarle Asset Management

Albemarle Asset Management was founded in London in 2003. The company provides both individual and collective management services for private and institutional investors, financial and capital management consultancy, and managed investment solutions. Our services cover global financial markets and our expertise enables us to offer diverse set of investment instruments and


Performance *

	YTD	1M	6M	1YR	Inception
Fund	4.72%	-2.00%	-4.60%	-1.00%	-3.05%
	Best Month	Worst Month	CAGR	Volatility	Sharpe Ratio
Fund	9.89%	-9.12%	-0.61%	11.68%	-0.37

Chart Performance *



Returns *



Different Share Classes

Class	NAV	YTD	1M	6M	1YR	Since Inception	Inception Dat	ISIN	Management Fee
A	Daily	4.59%	-2.06%	-4.96%	-1.74%	-4.53%	05/02/2020	IE00B3BM9X16	1.5% p.a.

Albemarle Asset Management Limited, 21 Upper Brook Street, London W1K 7PY

Tel: +44 (0)2072907730 - www.albemarleasset.com - albemarlefunds@albemarleasset.com

Fund Objective

Albemarle Longevity Fund is an open-end fund incorporated in Ireland. The Fund aims to achieve long term capital appreciation by investing in stocks which could benefit the most from the long-term demographic trend of an ageing population.

Fund Information

Company	Albemarle Funds Plc
Investment Manager	Albemarle Asset Management Ltd
Bloomberg	ATGASII ID
ISIN	IE00B50NJG20
Inception	05/02/2020
Currency	EUR
Fund Manager	Albemarle Asset Management Ltd
Management Fees	0.75% p.a.
Benchmark	N/A
Performance Fees	15% of the amount by which the net asset value exceeds the high water mark
NAV	Daily
Cut-Off	T-1 before 1pm Irish Time
Settlement date f/T+2 Irish Business Days	
Settlement date f/T+2 Irish Business Days	
Domicile	Ireland
Auditors	Grant Thornton
Depositary	Northern Trust Fiduciary Services (Ireland) Ltd
Category	UCITS V


Important Information

The information contained within this document is for the use of Institutional and Professional Investors only

Source: Bloomberg

* Please note the strategy of the fund changed on February 5th, 2020


Sector Breakdown Net Exposure (%)




Top Holdings

GERRESHEIMER AG	3.17%
STRAUMANN HOLDING AG-REG	2.95%
ASTRAZENECA PLC	2.89%
TRIGANO SA	2.89%
MELIA HOTELS INTERNATIONAL	2.78%
Total	14.68%

Asset Allocation Exposure (%)



Country Breakdown Net Exposure (%)



Commentary

The Fund posted a negative performance in February after the strong gain registered in January, amid a weak performance of the Life Science sector. The main positive contributors to the Fund performance during the month had been Gerresheimer, Genmab, Smith&Nephew, Astrazeneca and El.En. Gerresheimer jumped as the German maker of primary packaging for drugs and cosmetics confirmed that it is discussing with private equity investors on a potential takeover offer. Genmab outperformed as the Danish biotech firm reported operating profit for the fourth quarter ahead of analysts expectations and it announced a 2025 Ebit guidance ahead of consensus estimates at the midpoint. Smith&Nephew gained as the British medical company announced Q4 2024 results which topped expectations, with reassuring strength in particular at its U.S. orthopaedics business, and it announced a 2025 outlook in line with consensus. The main detractors to the Fund performance had been Stratec, Qiagen, Tecan, Sonova and Biotage. Qiagen fell after the German molecular-testing firm's initial 2025 outlook came out slightly below expectations. Tecan underperformed after one bank downgraded its recommendation on the stock of the Swiss laboratory instruments and solutions company citing potential for softer 2025 guidance and the risk coming from the US National Institutes of Health's plans to cut billions of dollars in reimbursements to medical researchers. During the month the main trades executed had been the sale of Recordati, Roche and Eckert&Ziegler, and the purchase of El.En, Equasens, Genmab and Qiagen.

Disclaimer

This information is being communicated by Albemarle Asset Management Limited, which is authorised and regulated by the Financial Conduct Authority. This material is for information only and does not constitute an offer or recommendation to buy or sell any investment, or subscribe to any investment management or advisory service. It is only directed and may only be distributed to persons who are Professional Clients or Eligible Counterparties and is not, under any circumstances, intended for distribution to the general public. With investment, your capital is at risk and the value of an investment and the income from it can go up as well as down, it may be affected by exchange rate variations and you may not get back the amount invested. Past performance is not necessarily a guide to future performance. We do not represent that this information, including any third party information, is accurate or complete and it should not be relied upon as such. Opinions expressed herein reflect the opinion of Albemarle Asset Management Limited and are subject to change without notice. No part of this document may be reproduced in any manner without the written permission of Albemarle Asset Management Limited, however recipients may pass on this document but only to others falling within this category. This information should be read in conjunction with the relevant fund documentation which may include the fund's prospectus, simplified prospectus or supplement documentation and if you are unsure if any of the products and portfolios featured are the right choice for you, please seek independent financial advice provided by regulated third parties.